Investigational Alzheimer's drug improves biomarkers of the disease
An investigational Alzheimer's drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at ...
Jun 21, 2021
0
12